Cannabidiol (abbreviated as: CBD) is one of at least 113 active cannabinoids identified in cannabis. It is a major phytocannabinoid, accounting for up to 40% of the plant's extract. CBD does not appear to have any psychoactive effects such as those caused by tetrahydrocannabinol (THC), and according to researchers, it may have a downregulating impact on disordered thinking and anxiety.

Researchers are just starting to uncover the potential for cannabinoids to treat medical conditions ranging from childhood epilepsy to aggressive cancers. While these compounds have shown strong promise, researchers have struggled to find ways to consistently and effectively deliver cannabinoids to desired parts of the body. Many products that are on the market right now are ineffective at delivering cannabinoids to improve outcomes.

YiLo is an emerging company engaged in the development and commercialization of therapeutic pharmaceuticals and nutraceuticals using innovative drug delivery platform technologies to deliver cannabinoids. YiLo aims to solve existing cannabinoid dosing and administration barriers by bringing pharmaceutical-grade delivery technologies into the industry. With acquisitions in the dermal and oral delivery technology space, the company is uniquely positioned to capitalize on the growing demand for innovative drug delivery solutions for patients.

Problems with Cannabinoid Delivery

Cannabinoids have the potential to treat many serious medical conditions, but researchers have struggled to find a reliable delivery mechanism. Cannabinoids that are inhaled bypass the liver and stomach and travel directly to the brain, but smoking cannabis has several adverse health effects. While oral cannabinoids solve these issues, they are metabolized in the liver and stomach where their potency is greatly diminished.

In a 2009 study, researchers found that THC bioavailability was between 2% and 56% for inhaled cannabis smoke and 4% to 20% for orally-consumed cannabinoids. Others researchers have found that THC was widely absorbed, but less than 1% of the administered dose reached the brain while the spleen and body fat became long-term storage sites. For patients looking for consistent dosing, these dynamics create a significant problem.Topical delivery has become a great alternative for many consumers – especially those with skin-related conditions – but these formulations often suffer from poor absorption, greasiness, and oiliness that makes them difficult for consumers to use.

Innovative New Delivery Systems

YiLo has recognized these problems and is focused on leveraging existing pharmaceutical drug delivery systems and formulating them with cannabinoids. By taking this approach, the company is confident that the technologies will deliver meaningful therapeutic benefits compared to current available products. Investors may want to take note of this fast growing company as it aims to develop a pipeline of products and make them commercially available in the near term.

YiLo’s consistent product dosing technology was developed and tested for multiple different products and has demonstrated the ability to specifically formulate and produce individual products to prolong natural release at steady therapeutic concentrations.

YiLo has collaborated closely with patients and consumers to develop and commercialize therapeutic pharmaceuticals and nutraceuticals to meet the growing demand for cannabinoid based products to overcome missing quality standards of ineffective products currently on the market.

Rigorous clinical studies are still needed to evaluate the final clinical potential of CBD for specific conditions. However, pre-clinical research (including both cell culture and animal models) has shown CBD to have a range of effects that may be therapeutically useful—including anti-seizure, anti-oxidant, neuroprotective, anti-inflammatory, analgesic, anti-tumor, anti-psychotic, and anti-anxiety properties.

Studies have shown benefits of CBD for the following ailments:

Anxiety

Depression

Psychosis

Alzheimer’s Disease

PTSD

OCD

Panic Disorder

Seizures/Convulsive Disorders

Multiple Sclerosis

Parkinson’s Disease

Epilepsy

Acne

Psoriasis

General Pain

Muscle Spasms

Antibiotic-resistant Infections

Cancer

Diabetes

Arthritis

This statement has not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease.